Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 8174. Отображено 100.
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
02-02-2012 дата публикации

Highly sensitive detection method for highly virulent oral cavity bacteria

Номер: US20120028879A1

Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of the hemolysis aggravation in a subject is assessed if a PA is not detected anchor a CBP is detected in the sample. Also provided are a detection reagent and kit for use in the method.

Подробнее
09-02-2012 дата публикации

Method for assessing inflammatory condition

Номер: US20120034706A1

Provided a method for correctly assessing an inflammatory condition of a patient who is receiving a therapy with an IL-6 inhibitor. The method for assessing an inflammatory condition of a patient who is receiving an IL-6 inhibitor, including determining a PTX3 level of a sample derived from a patient who is receiving an IL-6 inhibitor.

Подробнее
01-03-2012 дата публикации

Markers and methods for assessing and treating lupus patients susceptible to photoprovocation

Номер: US20120052066A1
Автор: Cesar Calderon, John Getsy
Принадлежит: Centocor Inc

A method for predicting or detecting susceptibility to lupus of an individual subjected to photoprovocation obtains biological samples from the individual before and after exposure to photoprovocation and compares the levels of at least a portion of members of a 45-member panel or subset thereof to determine whether the individual is susceptible to lupus. The method enables identification of potential lupus patients prior to onset of disease symptoms.

Подробнее
01-03-2012 дата публикации

Reagent kit for detecting lupus anticoagulant and method of determining presence or absence of lupus anticoagulant

Номер: US20120052585A1
Принадлежит: Sysmex Corp

The present invention provides a reagent kit for detecting LA which includes a first clotting time-measuring reagent containing manganese salt and a second clotting time-measuring reagent which contains manganese salt at a concentration lower than that of the first clotting time-measuring reagent or does not contain manganese salt and a method of determining the presence or absence of LA using the kit.

Подробнее
15-03-2012 дата публикации

Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents

Номер: US20120064532A1
Принадлежит: NOVARTIS AG

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

Подробнее
15-03-2012 дата публикации

Methods and kits for diagnosing osteoarthritis and predicting progression

Номер: US20120065094A1
Принадлежит: New York University NYU

This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.

Подробнее
29-03-2012 дата публикации

Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases

Номер: US20120076770A1
Принадлежит: Individual

THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone marrow, and bone tissue.

Подробнее
05-04-2012 дата публикации

Biomarkers, Methods and Kits for the Diagnosis of Rheumatoid Arthritis

Номер: US20120083423A1

The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with Rheumatoid Arthritis (RA). More specifically, the invention provides epitopes of PAD4, of BRAF, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of RA, in particular for the diagnosis of RA in CCP-negative subjects.

Подробнее
12-04-2012 дата публикации

Therapeutics for age-related macular degeneration

Номер: US20120087928A1
Автор: Kameran Lashkari
Принадлежит: Individual

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

Подробнее
24-05-2012 дата публикации

Methods and compositions for diagnosing ankylosing spondylitis using biomarkers

Номер: US20120129185A1
Принадлежит: Abbott Biotech Ltd Bermuda

The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.

Подробнее
24-05-2012 дата публикации

Detection and treatment of autoimmune disorders

Номер: US20120130350A1
Принадлежит: Seattle Childrens Hospital

Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.

Подробнее
14-06-2012 дата публикации

Methods of evaluating cells and cell cultures

Номер: US20120149013A1
Принадлежит: Genzyme Corp

Methods of evaluating the composition of a cell culture (e.g., to distinguish chondrocytes from fibroblasts) and methods for evaluating the phenotype of an individual cell (e.g., as a chondrocyte) are disclosed. The methods may be used, for example, for assessing chondrocyte cultures used for treatment of cartilage defects. In some embodiments, the invention involves identifying cell culture composition or the identity of a cell based on expression level of a fibroblast marker. In other embodiments, the invention involves comparing expression levels of at least one chondrocyte marker and at least one fibroblast marker in a cell culture sample or in an individual cell. In illustrative embodiments, the chondrocyte marker is hyaluronan and proteoglycan link protein 1 (HAPLN1), and the fibroblast marker is microfibrillar associated protein 5 (MFAP5).

Подробнее
23-08-2012 дата публикации

Diagnostic and Therapeutic Uses for B Cell Maturation Antigen

Номер: US20120213768A1
Принадлежит: BAYLOR RESEARCH INSTITUTE

Biomarkers and therapies against autoimmune diseases, including systemic lupus erythematosus (SLE) are described herein. The present invention is based on the discovery of B cell maturation antigen (BCMA) and BCMA variant expression on SLE monocytes that can be directly associated with disease activity. The findings of the present invention enable the design of monoclonal antibodies or recombinant proteins that can block BCMA and BCMA variants as well as BCMA-bound APRIL.

Подробнее
13-09-2012 дата публикации

Breath ketone detector

Номер: US20120231548A1
Автор: Raymond F. Akers, Jr.
Принадлежит: Akers Biosciences Inc

Ketoacidosis is an extreme and uncontrolled form of ketosis, which is a normal response to prolonged fasting. Embodiments of this invention test the ketone level of a patient by measuring the ketone bodies in breath condensation. Some embodiments include a device for medical testing comprising a hollow container, comprising powder mixture of sodium nitroferricyanide, ammonium sulfate and silica and a liquid including an ammonium hydroxide solution.

Подробнее
13-09-2012 дата публикации

Compositions and Methods for Treatment of Eye Disorders

Номер: US20120232019A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Подробнее
20-09-2012 дата публикации

Biomarkers for prognoses of pulmonary diseases

Номер: US20120237954A1
Автор: Steven R. Duncan
Принадлежит: University of Pittsburgh

The present invention relates to biomarkers that may be used to evaluate the prognoses of patients suffering from pulmonary diseases and assist in the determination of appropriate therapeutic regimens. It is based, at least in part, on the discovery that a number of T-cell antigens are differentially expressed in chronic lung disease patients depending on the prognosis of the patient. Non-limiting examples of these antigens include CD28, CD4, CD25, CD45, CD27 and CCR7 and combinations thereof. Use of these biomarker antigens, optionally in conjunction with pulmonary function tests, provides an indication of which patients are likely to suffer a severely adverse outcome within the year and/or be refractory to treatment.

Подробнее
29-11-2012 дата публикации

Novel use of ca-125

Номер: US20120301879A1

Provided is novel use of CA-125. As it is discovered that CA-125 level are positively associated with bone mineral density, thereby CA-125 can be used in biomarker to diagnose osteoporosis or osteopenia, or extent of growth plate development.

Подробнее
06-12-2012 дата публикации

Diagnostic oral device

Номер: US20120309042A1
Принадлежит: Colgate Palmolive Co

Described herein are devices and methods for identifying the existence of an oral condition in a subject.

Подробнее
27-12-2012 дата публикации

Methods of identifying obm modulators

Номер: US20120329671A1
Принадлежит: AMGEN INC

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Подробнее
17-01-2013 дата публикации

THERAPEUTIC USE OF THE ß2m PROTEIN

Номер: US20130017212A1
Принадлежит: BETA INNOV

The use of beta2-microglobulin (β2m) as active ingredient, in particular in pharmaceutical compositions intended for the treatment of autoimmune diseases.

Подробнее
21-03-2013 дата публикации

Methods for autoimmune disease diagnosis, prognosis, and treatment`

Номер: US20130071860A1
Принадлежит: Leland Stanford Junior University

In one aspect, the present invention provides methods for the classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome of an autoimmune disease in a subject.

Подробнее
04-04-2013 дата публикации

Method to detect tissue degradation leading to inflammation

Номер: US20130084584A1
Принадлежит: Individual

This invention relates generally to a method, an assay and a kit for determining a tissue degradation process that leads to inflammatory responses opening up for a vicious circle of increased tissue destruction. More specifically the invention relates to kits and methods for an assay that can analyzee human samples, for the presence of a COMP fragment complex that have activated complement exemplified by the complex between COMP and complement factor C3b or natural breakdown fragments of C3b.

Подробнее
02-05-2013 дата публикации

Optimized degenerative muscle disease diagnostics and treatments

Номер: US20130108646A1
Принадлежит: MEDIMMUNE LLC

Provided herein are optimized methods for treating a degenerative muscle disease, which comprise determining the presence, absence or amount of a biomarker associated with the disease after a drug has been administered, and determining whether a subsequent dose of the drug should be maintained, increased or decreased based on the biomarker assessment. Increased levels of certain biomarkers are linked to muscle degenerative diseases (e.g., GM-CSF(CSF2), TNF-alpha or other pro-inflammatory cytokine acting through NF kappa B), and decreased levels of certain biomarkers are linked to the muscle degenerative diseases 9 e.g., particular microRNA (e.g., miRNA-1, miRNA-133, miRNA-206)). Such methods optimize therapeutic efficacy and minimize toxicity associated with a drug. Also provided herein are therapeutics for treating muscle disorders.

Подробнее
02-05-2013 дата публикации

Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer

Номер: US20130109629A1
Принадлежит: Universitaetsklinikum Freiburg

The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity. The present invention also relates to a method for detecting an interstitial lung disease or a cancer in a subject by determining the level of CCR6 gene expression in a sample from said subject and further provides pharmaceutical compositions comprising inhibitors of CCR6 receptor activity and/or expression for the treatment of said diseases.

Подробнее
13-06-2013 дата публикации

Risk factors of cigarette smoke-induced spirometric phenotypes

Номер: US20130150250A1
Принадлежит: Individual

The technology provided herein relates to the SNPs identified as described herein, both singly and in combination, as well as to the use of these SNPs, and others in linkage disequilibrium with these SNPs, for diagnosis, prediction of clinical course, and/or treatment response for pulmonary disease such as COPD, development of new treatments for pulmonary disease such as COPD based upon comparison of the variant and normal versions of the gene or gene product, and development of cell-culture based and animal models for research and treatment of pulmonary disease such as COPD. The technology provided herein further relates to novel compounds, pharmaceutical compositions, and kits for use in the diagnosis, treatment, and evaluation of such disorders.

Подробнее
20-06-2013 дата публикации

Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract

Номер: US20130156703A1
Принадлежит: Ansun Biopharma Inc, NexBio Inc

The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Подробнее
27-06-2013 дата публикации

Compositions and methods to treat bone related disorders

Номер: US20130164284A1
Принадлежит: NOVARTIS AG

The present invention relates to the use of modulators of the sclerostin: sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin: sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided.

Подробнее
04-07-2013 дата публикации

Diagnostic Methods for Glaucoma

Номер: US20130172204A1
Принадлежит: M Lab AG

The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma. The invention further concerns a second diagnostic method for glaucoma comprising the steps of a) providing an in vitro culture of cells; b) incubating a body fluid from a test individual with the in vitro culture of cells or incubating components, which are fractionated from the body fluid or from a body specimen of the test individual with the in vitro culture of cells; c) analyzing protein expression of the cells and/or analyzing the viability of the cells after treatment according to step b); and d) comparing the results of the analysis in step c) with standard data to determine a diagnostic result.

Подробнее
11-07-2013 дата публикации

Novel c3c epitope, antibodies binding thereto, and use thereof

Номер: US20130177567A1
Принадлежит: Syddansk Universitet

Provided are antibodies directed against a novel epitope on the human C3 c (complement factor 3 c) and the use and manufacture thereof. Moreover, there is provided a novel immunogen for use in the preparation of the antibodies. The antibodies are in the first place of the monoclonal type.

Подробнее
08-08-2013 дата публикации

Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination

Номер: US20130202533A1
Принадлежит: Harvard College

This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.

Подробнее
08-08-2013 дата публикации

Autotaxin pathway modulation and uses thereof

Номер: US20130202614A1
Автор: Vassilios Aidinis
Принадлежит: B S R C "ALEXANDER FLEMING"

Disclosed are methods for preventing, treating, or reducing symptoms of a disorder involving the autotaxin (ATX) pathway. In one embodiment, the method features administering to a mammal a sufficient amount of an autotaxin (ATX) or lysophosphatidic acid (LPA) signaling inhibitor, to prevent, treat or reduce symptoms of an inflammatory disorder, autoimmune disorder, fibrosis or malignancy of the lung. Further disclosed are methods for diagnosing an autotaxin-related disorder as well as kits for performing the methods of the invention.

Подробнее
08-08-2013 дата публикации

Methods and means for diagnosing spondylarthritis using autoantibody markers

Номер: US20130203088A1
Принадлежит: MEDIZINISCHE HOCHSCHULE HANNOVER

The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis. In particular, detection of the presence of autoantibodies against CD74 and/or IKBKB allows early diagnosis of Spa, in particular, AS and undifferentiated spondyloarthritis.

Подробнее
22-08-2013 дата публикации

Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses

Номер: US20130216553A1
Принадлежит: University of Connecticut

A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison is indicative of the inflammatory or the autoimmune condition. An example of the autoimmune condition is multiple sclerosis. According to one embodiment, an increased ratio of phosphoglycerol dihydroceramide (PG DHC) to phosphoethanolamine dihydroceramide (PE DHC) in a blood sample indicates a presence of MS in the source patient. The use of PDHCs as biomarkers for detection of MS is described. Antibodies specific to PG DHC or PE DHC are also provided, along with their uses. Also provided are compositions comprising bacteria-originated lipids useful for modulation of immune responses or TLR pathways in humans, animals, and human or animal cells or tissues.

Подробнее
12-09-2013 дата публикации

Biomarker normalization

Номер: US20130233061A1
Автор: Benjamin Sullivan
Принадлежит: UNIVERSITY OF CALIFORNIA

A fluid sample is measured with a tear film measuring system that includes is processing device that receives a sample chip comprising a sample region configured to contain an aliquot volume of sample fluid, the processing device configured to perform analyses of osmolarity and of one or more biomarkers within the sample fluid, wherein the analysis of biomarkers includes normalization of biomarker concentration values.

Подробнее
10-10-2013 дата публикации

Method of determining risk of scoliosis

Номер: US20130266966A1
Автор: Alain Moreau
Принадлежит: CHU SAINTE-JUSTINE

A method for determining the risk for developing a scoliosis comprising monitoring osteopontin (OPN) expression in a sample from a subject over time; wherein an OPN expression that increases in the subject sample over time is indicative that the subject is at risk for developing a scoliosis.

Подробнее
21-11-2013 дата публикации

Hybridoma cell line for producing antibody for type ii collagen

Номер: US20130309694A1
Принадлежит: I-SHOU UNIVERSITY

The present invention provides a hybridoma cell line (DSM ACC3145), wherein the hybridoma cell line produces an antibody which specifically binds to an amino acid sequence of type II collagen comprising: K-G-E-P-G-D-D-G-P-S-C (as set forth in SEQ ID NO. 1); and a method for detecting osteoarthritis, by identifying a presence of type II collagen in a urine sample through containing the urine sample with the said antibody.

Подробнее
19-12-2013 дата публикации

Method and Kit for Determining Severity and Progression of Periodontal Disease

Номер: US20130337448A1
Принадлежит: Interleukin Genetics Inc

An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patient's predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.

Подробнее
02-01-2014 дата публикации

Fen1 as a marker for chronic obstructive pulmonary disease (copd)

Номер: US20140004544A1
Принадлежит: Roche Diagnostics Operations Inc

An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro.

Подробнее
16-01-2014 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20140018250A1
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
30-01-2014 дата публикации

Antibody reacting with native cochlin-tomoprotein (ctp) and method for measuring ctp using same

Номер: US20140030742A1
Принадлежит: Saitama Medical University

An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP).

Подробнее
20-02-2014 дата публикации

Transglutaminase-2 inhibitors and uses thereof

Номер: US20140050779A1
Принадлежит: SINGAPORE HEALTH SERVICES PTE LTD

The present invention refers to a method of treating a disease or disorder associated with the expression of at least one transgluaminase-2 and a method of identifying a candidate transglutaminase-2 inhibitor.

Подробнее
13-03-2014 дата публикации

Osteoporosis associated markers and methods of use

Номер: US20140072571A1
Принадлежит: Tethys Bioscience Inc

Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.

Подробнее
07-01-2016 дата публикации

CTHRC1 RECEPTOR AND METHODS OF USE THEREOF

Номер: US20160000866A1
Принадлежит:

The invention features compositions and methods for treating and preventing steatosis, osteoporosis, and muscle weakness featuring the receptor for the collagen triple helix repeat containing-1 (Cthrc1) protein. 1. A method of treating or preventing steatosis or a steatosis-associated condition in a subject , the method comprising:identifying a subject having or at risk of developing steatosis or a steatosis-associated condition;administering to the subject an effective amount of a Collagen Triple Helix Repeat Containing 1 (Cthrc1) polypeptide or a Cthrc1 receptor agonist, thereby treating or preventing steatosis or a steatosis-associated condition in the subject.2. The method of claim 1 , wherein said steatosis or a steatosis-associated condition is selected from the group consisting of hepatic steatosis and cardiac steatosis.3. The method of claim 1 , wherein the composition is administered systemically.4. The method of claim 1 , wherein the effective amount of Cthrc1 polypeptide or Cthrc1 receptor agonist is sufficient to reduce lipids in target organs by at least 5%.5. The method of claim 1 , wherein the Cthrc1 receptor comprises G Protein-Coupled Receptor 180 (GPR180).6. A method of treating or preventing low bone mass or a low bone mass-associated condition in a subject claim 1 , the method comprising:identifying a subject having or at risk of developing low bone mass or a low bone mass-associated condition;administering to the subject an effective amount of a Cthrc1 polypeptide or a Cthrc1 receptor agonist, thereby treating or preventing low bone mass or a low bone mass-associated condition in the subject.7. The method of claim 6 , wherein the low bone mass or low bone mass-associated condition comprises osteoporosis.8. The method of claim 6 , wherein the composition is administered systemically.9. The method of claim 6 , wherein the effective amount of Cthrc1 receptor agonist is sufficient to increase bone mass by at least 5%.10. The method of claim 1 , ...

Подробнее
07-01-2016 дата публикации

Biomarkers for inflammatory disease and methods of using same

Номер: US20160000936A1
Принадлежит: AbbVie Inc

The invention provides methods for predicting the efficacy of anti-TNF and anti-IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-1β, IL-1Ra, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCR1, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject.

Подробнее
07-01-2016 дата публикации

REAGENT FOR DIAGNOSIS OF OSTEOARTHRITIS COMPRISING PEPTIDE PROBE OF APOPEP-1

Номер: US20160000938A1
Принадлежит:

Disclosed is a reagent for diagnosing osteoarthritis or predicting the prognosis of osteoarthritis, the reagent containing a peptide having the amino acid sequence (CQRPPR) of SEQ ID NO: 1 as an active ingredient. The present peptide can be used to accurately diagnose osteoarthritis in its early stage based on the molecular imaging technique. The present peptide has a small molecular weight, and thus has advantages of fast clearance from the blood, effective permeation into the tissue, low immunogenicity, and low-production cost. Further, the present reagent can diagnose osteoarthritis in its early stage in which the destruction of cartilage is in a reversible phase and thus can be recovered to a normal state, thereby significantly contributing to effective treatment of osteoarthritis. 1. A method for detecting osteoarthritis of a subject comprising:(a) administering to the subject or chondrocytes obtained from the subject a peptide probe containing (i) a peptide comprising the amino acid sequence of SEQ ID NO: 1 and (ii) a label generating a detectable signal and linked to the peptide;(b) determining the level of the peptide in the subject or the chondrocytes by measuring signal generated from the peptide probe; and(c) comparing the level of the peptide in the subject or chondrocytes, with the level of the peptide in a normal subject or normal chondrocytes, wherein an increased level of the peptide in the subject indicates an increased severity of osteoarthritis of the subject.2. The method according to claim 1 , wherein the subject is a human claim 1 , a mouse claim 1 , a rat claim 1 , a hamster claim 1 , a rabbit claim 1 , a guinea pig claim 1 , a dog or a primate.3. The method according to claim 1 , wherein the peptide binds to the chondrocytes.4. The method according to claim 1 , wherein the chondrocytes are apoptotic chondrocytes.5. The method according to claim 1 , wherein osteoarthritis is in its early stage.6. The method according to claim 5 , wherein ...

Подробнее
03-01-2019 дата публикации

SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS

Номер: US20190000921A1
Автор: TOUBI Elias, Vadasz Zahava

The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof. 1. A method for determining efficacy of a treatment for Systemic Lupus Erythematosus in a subject in need thereof , the method comprising:making a first measurement of serum Semaphorin 3A concentration in a subject in need thereof prior to administration of a treatment for Systemic Lupus Erythematosus to the subject; making a second measurement of serum Semaphorin 3A concentration in the subject following said treatment; and comparing said first measurement and said second measurement, wherein an increase in serum Semaphorin 3A concentration from the first to the second measurement is indicative of said treatment being efficacious.2. The method of claim 1 , wherein said efficacy is further indicated by at least one clinical outcome selected from the group consisting of: an improvement in renal function claim 1 , a decrease in anti-dsDNA antibody concentration in the serum claim 1 , a decrease in anti-Cardiolipin antibody concentration in the serum claim 1 , an increase in serum concentration of complement factor C3 and an increase in serum concentration of complement factor C4.3. The method of claim 1 , wherein said efficacy is further indicated by a decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) value of said subject.4. The method of claim 1 , wherein said treatment for Systemic Lupus Erythematosus is selected from the group consisting of: a corticosteroid claim 1 , a cytotoxic drug claim 1 , a non-steroidal anti-inflammatory drug claim 1 , an anti-malarial drug claim 1 , a disease-modifying anti-rheumatic drug ...

Подробнее
06-01-2022 дата публикации

METHODS FOR TARGETED ASSESSMENT AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ACUTE EVENTS AND MORTALITY ASSOCIATED THEREWITH

Номер: US20220003785A1
Принадлежит:

Provided herein are methods for assessing a disease score of a subject suffering from or suspected to be suffering from chronic obstructive pulmonary disease (COPD) or associated disease mechanisms, wherein the disease score represents COPD activity or a risk of a severe acute COPD event or mortality. The disease score can be used to stratify the subject into a specific risk category and can further inform patient management decisions. The methods can involve determining a biomarker signature including two or more biomarkers associated with COPD or COPD mechanisms. In some cases, the methods include timing of collection of patient samples with respect to acute event or treatment course. Further provided herein are methods for identifying and/or treating subjects having a greater risk of developing COPD exacerbations. 1. A method of detecting protein , comprising:(a) obtaining a biological sample from a subject, wherein said biological sample comprises proteins and wherein said subject has or is suspected of having chronic obstructive pulmonary disease (COPD) and has not had a recent history of a severe acute COPD-related event;(b) detecting a level of one or more first proteins selected from the group consisting of: growth/differentiation factor 15 (GDF-15), pentraxin 3 (PTX3), c-reactive protein (CRP), serum amyloid A1 (SAA1), alpha-2-macroglobulin, cathepsin S, and complement component 1q (C1q); and 'wherein said one or more first proteins and said one or more second proteins are different.', '(c) detecting a level of one or more second proteins selected from the group consisting of: GDF-15, PTX3, cystatin-C, cathepsin S, D-dimer, chitinase-3-like protein 1 (YKL-40), CRP, SAA1, neutrophil elastase, N-terminal proatrial natriuretic protein (NTproANP), leptin, eotaxin-1, matrix metallopeptidase 9 (MMP-9), soluble receptor for advanced glycation end products (sRAGE), immunoglobulin G (IgG), immunoglobulin E (IgE), alpha-2-macroglobulin, immunoglobulin G1 (IgG1), and ...

Подробнее
05-01-2017 дата публикации

TRANS-DIFFERENTIATION OF DIFFERENTIATION CELLS

Номер: US20170002316A1

The present invention comprises methods and compositions related to trans-differentiating differentiated cells, the methods comprising bringing said cells into contact with a polypeptide or a nucleic acid encoding said polypeptide. 1. A method of trans-differentiating differentiated cells , the method comprising bringing said cells into contact with at least one component (i) and at least one component (ii) , whereinsaid component (i) is selected from(a) a polypeptide comprising at least one domain selected from a BH1, a BH2, a BH3 and a BH4 domain;(b) a polypeptide comprising or consisting of the amino acid sequence of a wild-type form of a member of the Bcl-2 family or a fragment thereof;(c) a polypeptide comprising or consisting of the amino acid sequence of a wild-type form of a member of the Bcl-2 family or a fragment thereof, wherein said polypeptide comprises one or more point mutations as compared to said wild-type form or fragment thereof;{'sub': 'L', '(d) a polypeptide comprising or consisting of an amino acid sequence which sequence exhibits at least 30% sequence identity with a wild-type form of a member of the Bcl-2 family, said wild-type form of a member of the Bcl-2 family preferably being selected from human Bcl-2 (SEQ ID NO: 1 or 5), human Bcl-X(SEQ ID NO: 6), human Bcl-w (SEQ ID NO: 7), human Mcl1 (SEQ ID NO: 8), human BfI1 (SEQ ID NO: 9 or 10), human Nrh (SEQ ID NO: 11), human Bcl2L1 (SEQ ID NO: 12), human DIVA (SEQ ID NO: 13), human myeloid cell leukemia sequence 1 isoform 1 (SEQ ID NO: 14), and human Bcl-x beta (SEQ ID NO: 15);'}wherein said wild-type form has anti-apoptotic activity;a nucleic acid encoding said polypeptide; andmeans for enhancing the amount and/or activity of said polypeptide in said cells;wherein said component (i) enhances the yield of trans-differentiated cells by at least 30% as compared to the absence of said component (i);andwherein said component (ii) is selected from a transcription factor capable of trans- ...

Подробнее
05-01-2017 дата публикации

DIAGNOSTIC AND IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR DISEASE STATES MEDIATED BY INHIBITOR-RESISTANT CD8 T-CELLS

Номер: US20170002419A1
Автор: Johnson Raymond M.
Принадлежит:

A previously unknown T cell receptor (TCR) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mTOR inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative TCR activation pathway uniquely exists in a subset of CD8 T cells expanded in the setting of chronic rejection or rheumatoid arthritis. Expansion of this newly discovered calcineurin and mTOR inhibitor resistant CD8 T cell subset in humans can be quantified by measuring levels of certain biomarkers in the circulating CD8 T cell pool, such as Pla2g4a, to diagnose disease states mediated thereby. Additionally, methods for diagnosing ongoing active inflammation mediated by this resistant CD8 T cell subset in either chronic rejection or rheumatoid arthritis are provided, which comprise measuring levels of the biomarker Scin in the circulating CD8 T cell pool. 1. A method of diagnosing a condition in a subject comprising the steps of:purifying a population of CD8 T cells collected from peripheral blood of a subject;isolating RNA from the purified CD8 T cells; andquantifying a level of expression of a Scin biomarker in the isolated RNA;wherein any expression of the Scin biomarker is indicative of the subject experiencing an active condition mediated by a subset of CD8 T cells that are resistant to calcineurin and mTOR inhibitors.2. The method of claim 1 , wherein the population of CD8 T cells is a circulating CD8 T cell population from a mononuclear cell fraction of the peripheral blood.3. The method of claim 1 , wherein:the step of purifying a population of CD8 T cells is performed using magnetic bead purification; andthe step of quantifying a level of expression of a Scin biomarker further comprises performing reverse transcription polymerase chain reaction on the isolated RNA and producing a semi-quantitative visualization ...

Подробнее
02-01-2020 дата публикации

PULMONARY HYPERTENSION BIOMARKER

Номер: US20200002768A1
Принадлежит:

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent. 1. A method for treating a patient having pulmonary hypertension , comprisingassaying the biological sample selected from blood, serum and plasma obtained from the patient for the level of CCL21 expression and/or CCL21 protein;b) comparing the amount of CCL21 expression and/or of CCL21 protein to a baseline value that is indicative of the amount of CCL21 expression and/or of CCL21 protein in a subject that does not have pulmonary hypertension; andc) administering a therapeutically effective amount of a pulmonary hypertension antagonist if the patient has a statistical significant increased amount of CCL21 expression and/or of CCL21 protein compared to the baseline value.2. (canceled)3. (canceled)4. The method according to claim 1 , wherein the step of assaying comprises assaying the biological sample for a nucleic acid sequence of CCL21 expression.5. The method according to claim 4 , wherein the nucleic acid is selected from CCL21 ribonucleic acid (RNA) or a fragment thereof and complementary deoxyribonucleic acid (cDNA) or a fragment thereof6. The method of claim 1 , wherein the step of assaying comprises assaying the biological sample for a CCL21 protein or fragment thereof7. (canceled)8. The method of claim 1 , wherein the step of assaying comprises a technique selected from Northern blot analysis claim 1 , polymerase chain reaction (PCR ...

Подробнее
05-01-2017 дата публикации

Porous semiconductor metal oxide complex nanofibers including nanoparticle catalyst functionalized by nano-catalyst included within metal-organic framework, gas sensor and member using the same, and method of manufacturing the same

Номер: US20170003272A1

The inventive concepts relate to a member for a gas sensor, a gas sensor using the same, and a method of manufacturing the same. More particularly, the inventive concepts relate to a gas sensor member using a porous semiconductor metal oxide complex nanofiber functionalized by uniformly distributing porous first metal oxide particles, including metal nanoparticle catalysts synthesized using a metal-organic framework, in the inside and on a surface of a second metal oxide nanofiber, a gas sensor using the same, and a method of manufacturing the same.

Подробнее
05-01-2017 дата публикации

METHODS FOR DETECTION OF RESPIRATORY DISEASES

Номер: US20170003300A1
Автор: BOWLER Russell P.
Принадлежит:

Disclosed are methods of identifying, predicting and treating subjects at risk for exacerbation or the presence of a respiratory disease, by detecting expression levels of one or more proteins associated with the respiratory disease, wherein said one or more proteins is selected from the group of CCL24, IL2RA, APOA4, GC, IgA, LPA, KLK3 F, FAS, NRCAM, TNFRSFIOC, IL12B, IL23A, RAGE, CCL20, ICAM1, SERPINA7, CDH13 and CDH1, and wherein said respiratory disease may be chronic obstructive pulmonary disease or emphysema. 1. A method of identifying a subject at risk of exacerbation of a respiratory disease comprising:a. obtaining a biological sample from the subject;b. determining the expression level of at least one protein associated with the respiratory disease in the biological sample from the subject, wherein the protein is selected from the group consisting of CCL24, IL2RA, APOA4, GC, IgA, LPA, KLK3_F, FAS, NRCAM, TNFRSF10C, IL12B, IL23A and combinations thereof; andc. identifying the subject as at risk of exacerbation when the expression level of the at least one protein is altered as compared to the expression of level of the least one protein from a control.2. The method of claim 1 , wherein determining the expression level of at least one protein associated with the respiratory disease comprises comparing the expression level of the at least one protein associated with the respiratory disease from the subject with the expression level of the at least one protein from a control claim 1 , wherein the expression level of the least one protein is considered altered if the expression level of the least one protein as compared to the expression level from the control is increased or decreased.3. (canceled)4. (canceled)5. The method of claim 1 , wherein the at least one protein comprises a protein selected from the group consisting of CCL24 claim 1 , IL2RA claim 1 , APOA4 claim 1 , GC claim 1 , IgA claim 1 , LPA claim 1 , KLK3_F and combinations thereof.6. The method of ...

Подробнее
07-01-2021 дата публикации

METHODS FOR ASSESSING RESPONSIVENESS TO ASTHMA TREATMENT BASED ON VNN-1 EXPRESSION AND PROMOTER METHYLATION

Номер: US20210002723A1
Принадлежит: CHILDREN'S HOSPITAL MEDICAL CENTER

Provided herein are methods and kits related to use of vanin-1 (VNN1) expression for assessing responsiveness to steroid treatment in subjects with asthma and for treating subjects with asthma. 126-. (canceled)27. A method of treating a subject with asthma , the method comprising:administering an effective amount of cysteamine or a pharmaceutically acceptable salt thereof to a subject having asthma, wherein the subject does not respond to a steroid treatment.2831-. (canceled)32. The method of claim 27 , wherein the pharmaceutically acceptable salt of cysteamine is cysteamine bitartrate or cysteamine hydrochloride.33. The method of claim 27 , wherein the cysteamine is in disulfide form.34. The method of claim 27 , further comprising applying to the subject a non-steroid treatment for asthma.35. The method of claim 34 , wherein the non-steroid treatment involves a mast cell stabilizer claim 34 , a leukotriene modifier claim 34 , an immunomodulator claim 34 , or a combination thereof.36. The method of claim 27 , wherein the subject is a human patient free of steroid treatment.37. The method of claim 27 , wherein the cysteamine or the pharmaceutically acceptable salt thereof is administered to the subject orally or by injection.38. The method of claim 27 , wherein the cysteamine or the pharmaceutically acceptable salt thereof is formulated in a pharmaceutical formulation claim 27 , which is in an enteric-coated solid form or in a sustained-release form.39. The method of claim 27 , wherein the subject is a human adult.40. The method of claim 27 , wherein the subject is a human child who is 18 years old or younger. This application is a national stage filing under 35 U.S.C. § 371 of PCT International Application No. PCT/US2015/030984, which has an international filing date of May 15, 2015, and claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application No. 61/994,477, filed May 16, 2014, the contents of each of which are incorporated by reference herein in ...

Подробнее
13-01-2022 дата публикации

3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

Номер: US20220008427A1
Принадлежит:

Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein. 2. The method of claim 1 , wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2 claim 1 ,6-dione or a pharmaceutically acceptable salt claim 1 , solid form claim 1 , solvate claim 1 , hydrate claim 1 , or tautomer thereof.3. The method of claim 1 , wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2 claim 1 ,6-dione.4. The method of claim 1 , wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2 claim 1 ,6-dione hydrochloride.5. The method of claim 1 , wherein the SLE is skin predominant SLE.711-. (canceled)12. The method of claim 1 , wherein administration of the compound continues for a period of from about 2 weeks to about 16 weeks.13. The method of claim 1 , wherein administration of the compound continues for a period of about 28 days.14. The method of claim 1 , wherein administration of the compound continues for a period of about 56 days.15. The method of claim 1 , wherein administration of the compound continues for a period of about 84 days.16. The method of claim 1 , wherein the compound is administered orally.17. The method of claim 16 , wherein the compound is administered in a capsule.18. (canceled)19. The method of claim 16 , wherein the compound is administered in a tablet.2135-. (canceled)3761-. (canceled)62. The method of claim 1 , wherein the SLE is severe SLE.63. The method of claim 1 , wherein the patient has Cutaneous Lupus Area and Severity Index (CLASI) Activity Score ≥10.64. The method of claim 6 , wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2 claim 6 ,6-dione or a pharmaceutically acceptable salt claim 6 , solid ...

Подробнее
01-01-2015 дата публикации

BIOMARKER FOR BARRETT'S OESOPHAGUS

Номер: US20150004622A1
Принадлежит: Medical Research Council

The present invention, relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods. 116.-. (canceled)17. A non-endoscopic method of aiding in the diagnosis of Barrett's esophagus (BE) in a subject comprising:obtaining a sample of cells from the subject using a swallowable device comprising an abrasive material adapted to collect at least some columnar cells in the sample of cells; anddetermining the presence of a biomarker in the sample of cells, wherein the presence of the biomarker is indicative of the subject having BE.18. The method of claim 17 , wherein the biomarker is Trefoil factor 3 (TFF3).19. The method of claim 17 , wherein the sample of cells comprise a mixed population of cells taken from a surface of the subject's esophagus.20. The method of claim 17 , wherein the sample of cells comprise esophageal cells and gastric mucosa cells.21. The method of claim 17 , wherein the subject does not present with BE lesions.22. The method of claim 17 , wherein the swallowable device comprises a capsule sponge.23. The method of claim 17 , wherein the specificity and sensitivity of the method of aiding in the diagnosis of (BE) are about 80% and about 65% respectively.24. The method of claim 17 , wherein the specificity and sensitivity of the method of aiding in the diagnosis of (BE) are about 94% and about 78% respectively.25. The method of claim 18 , wherein the TFF3 is detected in an immunoassay using an antibody specific for TFF3.26. The method of claim 18 , wherein the TFF3 is detected using an immunohistochemical detection method.27. The method of claim 17 , further comprising staining the sample of cells with an Alcian Blue stain to confirm diagnosis of BE.28. The method of claim 17 , wherein the abrasive material comprises polyurethane.29. The method of claim 17 , wherein the size and abrasiveness of the material is configured to sample substantially the entire esophageal surface of the subject. [ ...

Подробнее
04-01-2018 дата публикации

Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd

Номер: US20180003710A1
Принадлежит: Roche Diagnostics Operations Inc

The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, comprising measuring the concentration of anti-CCP and anti-PIK3CD and correlating the concentrations determined to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method of the invention. Further the invention relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).

Подробнее
04-01-2018 дата публикации

DIAGNOSIS OF LEUKOCYTE-MEDIATED DISEASE AND HALOGEN GAS EXPOSURE

Номер: US20180003726A1
Принадлежит:

Described are glutathione adducts of fatty aldehydes (FALD-GSH) and methods useful in the detection of FALD-GSH in the identification of pathologies associated with leukocyte-mediated disease conditions, including eosinophil and neutrophil activation. Thus, the present disclosure provides methods of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising (a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample; (b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and (c) diagnosing the subject as having or being at risk of developing LMD if the level of FALD-GSH in the sample is higher than the control or standard. 1. A method of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising:(a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample;(b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and(c) diagnosing said subject as having or being at risk of developing LMD if the level of FALD-GSH in said sample is higher than said control or standard.2. The method of claim 1 , wherein said sample is blood claim 1 , plasma claim 1 , serum claim 1 , sputum claim 1 , urine claim 1 , nasal swab claim 1 , or ear wax.3. The method of claim 1 , wherein said subject is suspected of having LMD.4. The method of claim 1 , wherein said subject exhibits one or more symptoms of LMD.5. The method of claim 1 , wherein said subject does not exhibit a symptom of LMD.6. The method of claim 1 , further comprising obtaining said sample from said subject.7. The method of claim 1 , wherein detecting comprises (i) mass spectrometry and/or high performance liquid chromatograph (HPLC) claim 1 , or (ii) binding of an antibody to FALD-GSH.8. The method of claim 7 , wherein an antibody ...

Подробнее
02-01-2020 дата публикации

Diagnostics Platform for Mitochondrial Dysfunctions/Diseases

Номер: US20200003762A1
Автор: Brown Stephen J.
Принадлежит:

The present invention concerns machine learning based methods and systems for diagnosing and treating genetic diseases characterized by mitochondrial dysfunctions. A library of reference learning models is developed based on in vitro reference samples obtained from cell-cultures exposed to specific mitochondrial inhibitors. Each model is able to predict a specific labeled mitochondrial dysfunction induced in the cell-culture by the inhibitor/stressor. The reference models are then applied to target samples drawn in vivo from target subjects who are known to have specific genetic mitochondrial diseases. A mapping is developed between mitochondrial dysfunctions predicted in the subjects and their known mitochondrial diseases. This mapping and the reference models are then applied to a clinical sample of an undiagnosed patient in whom a diagnosis of a mitochondrial dysfunction and an associated mitochondrial disease is made. If there is a known rescuer for the mitochondrial dysfunction, it may be recommended in a personalized, targeted therapy. 1. A diagnostic method comprising the steps of:(a) introducing in one or more dosages a mitochondrial inhibitor into each of one or more cell-cultures grown in vitro from one or more cell-lines, said mitochondrial inhibitor inducing a mitochondrial dysfunction into said each of one or more cell-cultures;(b) drawing from each of said one or more cell-cultures one or more reference samples at one or more times since said introducing;(c) making one or more reference biomarker measurements from corresponding each of said one or more reference samples;(d) learning by a learning module one or more reference models each able to predict said mitochondrial dysfunction in an unseen biomarker measurement, said learning module comprising a microprocessor executing program instructions stored in a non-transitory storage medium coupled to said microprocessor;(e) drawing from one or more target subjects one or more target samples in vivo and ...

Подробнее
01-01-2015 дата публикации

METHODS AND DEVICES FOR CLASSIFYING AND MANAGING AUTOIMMUNE AND INFLAMMATORY CONDITIONS

Номер: US20150005186A1
Автор: HUANG Jing-Feng
Принадлежит:

Devices and methods useful for biomarker-based diagnosis of immunopathological mechanisms involved in autoimmune or inflammatory diseases are described. 1. A diagnostic method for differentiating underlying immunopathological mechanisms in patients having an autoimmune or inflammatory condition , comprising:a. contacting a biological sample, optionally a tear sample, obtained from a subject known to have or suspected of having autoimmune or inflammatory disease with a plurality of detection reagent species that each independently binds a biomarker species associated with an immunopathological mechanism involved in an autoimmune or inflammatory disease different from biomarker species bound by the other detection reagent species; andb. using the detection reagent species to determine if the biomarker species associated with the immunopathological mechanism in patients having an autoimmune or inflammatory disease are present in amounts indicative of an autoimmune or inflammatory condition, optionally, dry eye disease.2. A method according to wherein the biomarker species include at least one biomarker species selected from the group consisting of IL-1beta claim 1 , IL-1alpha claim 1 , IL-1Ra claim 1 , IL-15 claim 1 , IL-7 claim 1 , IL-2 claim 1 , IL-3 claim 1 , IL-4 claim 1 , IL-5 claim 1 , IL-6 claim 1 , GM-CSF claim 1 , IL-18 claim 1 , IL-8 claim 1 , IL-12p70 claim 1 , IL-12p40 claim 1 , IL-17 claim 1 , IL-23 claim 1 , CXCL-10 claim 1 , ICAM-1 claim 1 , MIP-1alpha claim 1 , MIP-1 beta claim 1 , Complement 3 claim 1 , alpha1-antitrypsin claim 1 , apolipoprotein A1 claim 1 , apolipoprotein CIII claim 1 , and IgM claim 1 , and/or any of derivative or fragment of any of the foregoing.3. A method according to wherein at least one claim 1 , some claim 1 , or all of the detection reagent species comprise an antibody or antigen-binding antibody fragment.4. A method according to wherein the method comprises performing a multiplex immunoassay.5. A method according to wherein ...

Подробнее
07-01-2021 дата публикации

LOW SHEAR MICROFLUIDIC DEVICES AND METHODS OF USE AND MANUFACTURING THEREOF

Номер: US20210003561A1
Принадлежит:

Provided herein relates to systems and methods for producing and using a body having a central channel separated by one or more membranes. The membrane(s) are configured to divide the central channel into at least one mesochannel and at least one microchannel. The height of the mesochannel is substantially greater than the height of the microchannel. A gaseous fluid can be applied through the mesochannel while a liquid fluid flowing through the microchannel. The systems and methods described herein can be used for various applications, including, e.g., growth and differentiation of primary cells such as human lung cells, as well as any other cells requiring low shear and/also stratified structures, or simulation of a microenvironment in living tissues and/or organs (to model physiology or disease states, and/or to identify therapeutic agents and/or vaccines). The systems and methods can also permit co-culture with one or more different cell types. 1174-. (canceled)175. A method for culturing cells comprising: a. a body comprising a central channel therein; and', 'b. an at least partially porous membrane positioned within the central channel, the membrane configured to separate the central channel to format at least one microchannel and at least one mesochannel, wherein a height ratio of the at least one mesochannel to the at least one microchannel ranges from 10:1 to about 50:1;, '1) providing a microfluidic device comprising2) seeding human epithelial cells from a patient on said membrane facing the at least one mesochannel; and{'b': '2', '3) culturing the seeded human cells from step ) on said membrane submerged within a first liquid.'}176. The method of claim 175 , wherein the method further comprises:4) removing the first liquid from the at least one mesochannel, such that a gas-liquid interface is established, whereby said human cells are induced to differentiate into pseudostratified epithelial cells.177. The method of claim 175 , wherein the human epithelial ...

Подробнее
07-01-2021 дата публикации

Methods of detecting and treating pulmonary hypertension

Номер: US20210003583A1
Автор: Lawrence S. Zisman

The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.

Подробнее
07-01-2021 дата публикации

Pulse Stable Tracer Methods for Detection of Short-Chain Fatty Acids

Номер: US20210003589A1
Принадлежит: Texas A&M University

Provided herein are methods for determining a metabolic rate for at least one endogenous short-chain fatty acid in a subject, for diagnosing a pulmonary disease in a subject and for diagnosing a neurological disorder in a subject. Generally in the methods stable isotope labeled short-chain fatty acid are pulsed and metabolic rates are calculated in a first baseline blood sample and in a series of second blood samples obtained at intervals. The metabolic rates provide information about fatty acid metabolism and production. 1: A method for determining a metabolic rate for at least one endogenous short-chain fatty acid in a subject , comprising the steps of:a) drawing a baseline first blood sample from the subject;b) administering intravenously to the subject at least one stable isotope labeled short-chain fatty acid;c) drawing a series of second blood samples at intervals from the subject;d) measuring a concentration of the isotope in the first blood sample and in each of the series of second blood samples; ande) calculating a first metabolic rate of the at least one stable isotope labeled short-chain fatty acid from the concentrations of the isotope.2: The method of claim 1 , further comprising determining a deficiency in short-chain fatty acid production in the subject claim 1 , comprising:f) administering orally a soluble fiber to the subject; andg) repeating steps a) to e) to calculate a second metabolic rate for the at least one stable isotope labeled short-chain fatty acid; wherein a second metabolic rate substantially equal to the first metabolic rate indicates that short-chain fatty acid production in the subject is deficient.3: The method of wherein the soluble fiber is inulin claim 2 , oligofructose claim 2 , fructooligosaccharide or a combination thereof.4. (canceled)5: The method of claim 1 , wherein the subject is fasting prior to step a).6: The method of claim 1 , wherein the stable isotope labeled short-chain fatty acid is C-acetate claim 1 , C- ...

Подробнее
13-01-2022 дата публикации

ANIMAL MODELS AND SCREENING METHODS FOR INTRAOCULAR DISEASE OR DISORDER

Номер: US20220010352A1
Автор: Wei Lai
Принадлежит:

Provided are screening methods and animal models related to intraocular diseases such as age-related macular degeneration (AMD). For example, provided are screening methods for identifying candidate therapeutics for treating or preventing eye diseases, such as AMD. The screening method can be an in vitro screening method or an in vivo screening method, e.g., using an animal model described. Animal models are also provided herein, for example, for screening candidate therapeutics for treating or preventing eye diseases, such as AMD. Methods of preparing the animal models are also described. 2. The screening method of claim 1 , wherein the microorganism comprises a species that is enriched in the intraocular space (e.g. claim 1 , aqueous humor claim 1 , vitreous humor claim 1 , soft drusen) in a subject having age-related macular degeneration (AMD) compared to a healthy subject.3Staphylococcus epidermidis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas putida, Stenotrophomonas maltophilia, Bacillus cereus, Bacillus megaterium, Lactobacillus reuteri, Gardnerella vaginalis, Enterococcus faecium, Cytophaga hutchinsonii, Bacillus licheniformisXanthomonas oryzae.. The screening method of or claim 1 , wherein the microorganism comprises one or more species selected from claim 1 , and4Bacillus megateriumPseudomonas putida.. The screening method of any one of - claim 1 , wherein the microorganism comprises and/or5Bacillus megaterium.. The screening method of any one of - claim 1 , wherein the microorganism is a substantially biologically pure population of6. The screening method of any one of - claim 1 , wherein the microorganism comprises a mixture of microbial species substantially similar to those observed from an aqueous humor claim 1 , vitreous humor claim 1 , and/or soft drusen of a subject having age-related macular degeneration.7. The screening method of any one of - claim 1 , wherein the microorganism is derived claim 1 , in ...

Подробнее
03-01-2019 дата публикации

ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITIS

Номер: US20190004044A1
Принадлежит:

Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis. 1. A method for classifying an individual that is suffering from , or at risk of suffering from , a form of arthritis , the method comprising determining whether a sample comprising a body fluid of the individual comprises an anti-Carbamylated Fibrinogen (anti-Ca-Fib) antibody.2. A method for providing a prognosis for the development of arthritis to an individual suffering from arthritis , the method comprising determining whether a sample comprising a body fluid of the individual comprises an anti-Carbamylated Protein (anti-CarP) antibody and estimating the future severity of the arthritis based on the detection of the anti-CarP and/or anti-Ca-Fib antibody in the sample.3. The method according to claim 2 , wherein the body fluid is a serum sample or a synovial fluid sample.4. The method according to claim 2 , wherein the anti-CarP antibody is of Ig-subtype IgA or of the Ig-subtype IgG.5. A method for classifying an individual that is suffering from claim 2 , or at risk of suffering from claim 2 , a form of arthritis claim 2 , the method comprising determining whether a sample comprising a body fluid of the individual comprises an anti-Carbamylated Protein (anti-CarP) antibody claim 2 , wherein the sample is negative for anti-citrullinated Protein Antibody (ACPA) and wherein the detection of the anti-CarP antibody classifies the sample as a sample of an individual that is at high risk to be currently suffering from claim 2 , or at risk of developing claim 2 , arthritis.6. The method according to claim 5 , for determining whether the individual is at risk of suffering from arthritis claim ...

Подробнее
03-01-2019 дата публикации

Proteomics Based Diagnostic Detection Method for Chronic Sinusitis

Номер: US20190004046A1
Принадлежит:

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract. 151-. (canceled)52Haemophilus influenzae. A method of detecting the presence of nontypeable (NTHI) bacteria in the respiratory tract of a subject comprising the steps of: a) obtaining , by inserting a collection device into the patient's respiratory tract , a sample of secretions from the respiratory tract of the subject; and b) detecting the presence of at least one biomarker in the sample , wherein the biomarker is an outer membrane protein (OMP) by contacting the sample with antibodies specific for the OMP.53. The method of claim 52 , further comprising administering a therapeutic compound to the subject to reduce or eliminate the NTHI bacteria in the respiratory tract of the subject to treat one or more of: Otitis media claim 52 , bronchitis claim 52 , or pharyngitis.54. The method of claim 52 , wherein the OMP is selected from the group consisting of: high molecular weight adhesin 1 (HMW1) claim 52 , high molecular weight adhesin 2 (HMW2) claim 52 , outer membrane protein 5 (OMP P5) claim 52 , outer membrane protein P2 (OMP P2) claim 52 , IgA-protease claim 52 , putative periplasmic chelated iron binding proteins claim 52 , IgA-specific serine endopeptidase claim 52 , galactose-1-phosphate uridylyltransferase claim 52 , HMWA claim 52 , phosphate ABC transporter phosphate-binding ...

Подробнее
04-01-2018 дата публикации

COPD Biomarker Signatures

Номер: US20180004895A1
Принадлежит: Lineagen Inc

The present invention relates to methods of detecting differentially expressed protein expression indicative of COPD in a test sample. The detection of circulating levels of proteins within an identified COPD biomarker signature can aid in COPD diagnosis and disease monitoring, as well as in the prediction of responses to therapeutics. Evaluation of the biomarker signatures disclosed, or a subset of biomarkers thereof, provides a level of discrimination not found with individual markers.

Подробнее
20-01-2022 дата публикации

Treatment of Hearing Loss by Inhibition of Casein Kinase 1

Номер: US20220016100A1
Автор: Cheng Yenfu, Edge Albert
Принадлежит:

Methods for treating hearing loss that include administering an inhibitor, e.g., a small molecule inhibitor, of casein kinase 1, preferably in combination with a treatment that stimulates Atoh1 gene expression, e.g., a gamma-secretase inhibitor, an Atoh1 stimulatory compound, or a GSK-3-beta inhibitor. 1. A method of treating a subject who has or is at risk of developing hearing loss or vestibular dysfunction , comprising administering to the subject one or more inhibitory nucleic acids that target casein kinase 1 (CK1) epsilon and/or CK1 delta , and one or more compounds that stimulate Atoh1 gene expression.2. The method of claim 1 , wherein the subject has or is at risk for developing sensorineural hearing loss claim 1 , auditory neuropathy claim 1 , or both.3. The method of claim 1 , wherein the subject has or is at risk for developing a vestibular dysfunction that results in dizziness claim 1 , imbalance claim 1 , or vertigo.4. The method of claim 1 , wherein the one or more inhibitory nucleic acids that target CK1 epsilon and/or CK1 delta claim 1 , and/or the one or more compounds that stimulate Atoh1 gene expression is administered systemically.5. The method of claim 1 , wherein the one or more inhibitory nucleic acids that target CK1 epsilon and/or CK1 delta claim 1 , and/or the one or more compounds that stimulate Atoh1 gene expression is administered locally to the inner ear.6. The method of claim 1 , wherein the one or more inhibitory nucleic acids that target CK1 epsilon and/or CK1 delta is shRNA or siRNA.7. The method of claim 1 , wherein the method comprises administering to the subject one or more inhibitory nucleic acids that target CK1 epsilon.8. The method of claim 1 , wherein the method comprises administering to the subject one or more inhibitory nucleic acids that target CK1 delta.9. The method of claim 1 , wherein the one or more compounds that stimulate Atoh1 gene expression comprises a glycogen synthase kinase 3 beta (GSK-3-beta) inhibitor.10. ...

Подробнее
08-01-2015 дата публикации

PULMONARY HYPERTENSION

Номер: US20150010562A1
Автор: Lawrie Allan
Принадлежит: PH Therapeutics

The disclosure relates to agents that inhibit the activity of Tumour Necrosis Factor Apoptosis-Inducing Ligand [TRAIL] and their use in the treatment of pulmonary hypertension. 1. A method of treating pulmonary hypertension , comprising:administering to a subject having pulmonary hypertension an effective amount of an agent that inhibits expression of TRAIL or TRAIL protein activity, thereby treating the pulmonary hypertension.2. The method according to claim 1 , wherein said agent is an antagonistic antibody claim 1 , or active binding fragment thereof.3. The method according to claim 2 , wherein said antibody or binding fragment binds and inhibits the activity of a polypeptide comprising or consisting of the amino acid sequence in SEQ ID NO: 1 claim 2 , 2 or 3 claim 2 , or an antigen binding part thereof claim 2 , or a sequence variant that has between 75%-99% sequence identity with the amino acid sequence in SEQ ID NO: 1 claim 2 , 2 or 3.4. The method according to claim 3 , wherein said antibody binds a polypeptide comprising or consisting of the amino acid sequence in SEQ ID NO: 1 claim 3 , 2 or 3.5. The method of claim 2 , wherein said antibody competes with an antibody that binds to the amino acid sequence as represented in SEQ ID NO: 1 claim 2 , 2 or 3.6. The method of claim 2 , wherein said antibody is a polyclonal antibody.7. The method of claim 2 , wherein said antibody is a monoclonal antibody.8. The method of claim 2 , wherein said antibody binding fragment is selected from the group consisting of: Fab claim 2 , Fab claim 2 ,F(ab′) claim 2 , Fv claim 2 , Fc claim 2 , Fd claim 2 , and single chain antibody fragment.9. The method according to claim 7 , wherein said antibody is a chimeric antibody.10. The method according to claim 7 , wherein said antibody is a humanized or human antibody.11. The method of claim 2 , wherein said antibody or binding fragment binds the extracellular domain of TRAIL.12. The method according to claim 11 , wherein said antibody ...

Подробнее
08-01-2015 дата публикации

Targeted Delivery Of Autoantigens To B Cell Populations

Номер: US20150010584A1
Принадлежит: University of Massachusetts UMass

The present invention is related to compositions and methods to stimulate the immune system. For example, antigen-specific antibodies may be produced by stimulating B cell populations with specific antigenic compounds, such as an adjuvant comprising a macromolecule capable of activating a Toll-Like receptor (TLR). For example, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by TLR activation. Alternatively, a compound is described that inhibits TLR activation.

Подробнее
10-01-2019 дата публикации

MIRNA BIOMARKERS FOR CARTILAGE DEGENERATION

Номер: US20190008885A1
Принадлежит:

There is disclosed herein methods, uses and systems for the detection, diagnosis, prognosis, treatment or prevention of a disease or condition comprising cartilage degeneration in a subject that is in need thereof. The methods comprise the use, inhibition or measurement of at least one of miR-181 a-5p and miR-4454, in the subject. 1. A method of treating or preventing a disease or condition comprising facet cartilage degeneration in a subject in need thereof , the method comprising inhibiting at least one of miR-181a-5p and miR-4454 , in the subject.2. The method of claim 1 , wherein miR-181a-5p and miR-4454 are represented by SEQ ID NOs. 1 and 2.3. The method of claim 1 , wherein the inhibiting comprises administering to the subject a therapeutically effective amount of an inhibitor of at least one of miR-181a-5p and miR-4454 claim 1 , preferably directly injected at the site of the facet cartilage degeneration.4. The method of claim 1 , comprising inhibiting both of miR-181a-5p and miR-4454.5. The method of claim 3 , wherein the inhibitor is an antisense oligonucleotide having a nucleotide sequence that is complementary to at least 80% claim 3 , 90% claim 3 , 95% claim 3 , 98% claim 3 , 99% or 100% of SEQ ID NO: 1 or SEQ ID NO. 2.6. The method of claim 3 , wherein the inhibitor is an antisense oligonucleotide having a nucleotide sequence comprising SEQ ID NO: 3 or SEQ ID NO. 4 claim 3 , or a functional fragment thereof.7. The method of claim 6 , wherein the antisense oligonucleotide consists of SEQ ID NO. 3 or SEQ ID NO. 4.8. The method of claim 7 , wherein the antisense oligonucleotides is two antisense oligonucleotides consisting of SEQ ID NO. 3 and SEQ ID NO. 4.9. The method of claim 3 , wherein the inhibitor is an antisense oligonucleotide having at least 80% claim 3 , 90% claim 3 , 95% claim 3 , 98% or 99% sequence identity to any one of SEQ ID NO: 3 or SEQ ID NO: 4 claim 3 , or a functional fragment thereof.10. The method of claim 3 , wherein the inhibitor ...

Подробнее
12-01-2017 дата публикации

MARKER SEQUENCES FOR RHEUMATOID ARTHRITIS AND USE THEREOF

Номер: US20170009300A1
Принадлежит:

The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof. 1. A method for the diagnosis or risk stratification of rheumatoid arthritis comprising detecting an interaction between a body fluid or tissue extract of a patient and least one marker sequence of a cDNA selected from the group consisting of SEQ ID NO: 1-488 or a protein coding therefor , wherein detection of an interaction indicates the presence of rheumatoid arthritis in said patient.2. An arrangement of marker sequences comprising the marker sequences of the group SEQ ID NO: 1-488.3. The arrangement according to claim 3 , wherein the marker sequences are present as clones.4. The arrangement according to claim 3 , wherein the marker sequences are present on a solid support.5. A method of apheresis or blood lavage claim 3 , comprising contacting body fluid of a patient with the arrangement of marker sequences comprising the marker sequences of the group SEQ ID NO: 1-488. This application is a continuation of patent application Ser. No. 14/530,864 filed on Nov. 3, 2014, which is a continuation of patent application Ser. No. 12/676,223 filed on Mar. 3, 2010, which is a national stage application (under 35 U.S.C. §371) of PCT/DE2008/001547 filed Sep. 3, 2008, which claims benefit of German application 102007041656.5, filed Sep. 3, 2007, and German application, 102007041654.9, filed Sep. 3, 2007. The entire content of each above application is hereby incorporated by reference in its entirety.The Sequence Listing associated with this application is filed in electronic format via EFS-Web and hereby incorporated by reference into the specification in its entirety. The ...

Подробнее
08-01-2015 дата публикации

Cd8+t-cell subsets as markers for prediction of delayed fracture healing

Номер: US20150010924A1
Принадлежит: Charite Universitaetsmedizin Berlin

The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28− and CD8+CD28−/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.

Подробнее
08-01-2015 дата публикации

DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM

Номер: US20150011017A1
Принадлежит: BRAHMS GmbH

The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method. 1. Diagnostic marker consisting of CT-proADM (SEQ ID No. 1) , or partial peptides or fragments thereof.2. A method for diagnosing and/or stratifying the risk of diseases , comprising determining CT-proADM (SEQ ID No. 1) , or a partial peptide of fragment thereof , in a patient.3. The method of claim 2 , wherein the method is an in-vitro diagnosis.4. The method of claim 2 , wherein the diagnosis or risk stratification of diseases is an in vitro diagnosis or risk stratification of cardiovascular diseases claim 2 , cardiac insufficiency claim 2 , infections and/or inflammations of the lungs and respiratory.5. The method of claim 4 , wherein the cardiac diseases comprise a disease selected from the group consisting of high blood pressure claim 4 , coronary heart diseases claim 4 , especially acute coronary syndrome claim 4 , (acute) myocardial infarct claim 4 , and angina pectoris.6. The method of claim 4 , wherein the cardiac insufficiency comprises a chronic cardiac insufficiency claim 4 , hypertensive heart disease with (congestive) cardiac insufficiency claim 4 , hypertensive heart and kidney disease with (congestive) cardiac insufficiency claim 4 , primary right-ventricular heart failure claim 4 , secondary right-ventricular heart failure claim 4 , left-ventricular heart failure ...

Подробнее
08-01-2015 дата публикации

Systems and methods for characterizing lupus erythematosus

Номер: US20150011419A1
Принадлежит: Renovar Inc

The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis.

Подробнее
08-01-2015 дата публикации

Method for screening an agent being useful for the treatment of dry eye and /or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method

Номер: US20150011475A1
Принадлежит: R Tech Ueno Ltd

The present invention provides a method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to the report of the International Dry Eye WorkShop (DEWS Report) (2007) and a pharmaceutical composition comprising the agent. The present invention further provides a method for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to DEWS Report (2007) using the agent.

Подробнее
27-01-2022 дата публикации

METHOD OF SIMULTANEOUSLY DIAGNOSING ACTIVE TUBERCULOSIS AND LATENT TUBERCULOSIS INFECTION USING HUMAN WHOLE BLOOD SAMPLE-DERIVED BIOMARKER

Номер: US20220026417A1

The present invention relates to a method of simultaneously diagnosing active tuberculosis and latent tuberculosis infection (LTBI) using one or more biomarkers selected from a white blood cell count, a hemoglobin concentration, a neutrophil count, a lymphocyte count, a monocyte count, a procalcitonin concentration, a C-reactive protein concentration, an α1-acid glycoprotein concentration and an erythrocyte sedimentation rate, or a combination thereof. The present invention may provide a diagnostic method for simultaneously differentiating active tuberculosis and LTBI without a separate additional test on a patient diagnosed as positive by a conventional tuberculosis infection assay such as a tuberculin skin test (TST) or an interferon-γ release assay (IGRA). 1. A method of simultaneously diagnosing active tuberculosis and latent tuberculosis infection (LTBI) using one or more selected from a white blood cell count , a hemoglobin concentration , a neutrophil count , a lymphocyte count , a monocyte count , a procalcitonin concentration , a C-reactive protein concentration , an α1-acid glycoprotein concentration and an erythrocyte sedimentation rate , or a combination thereof as a biomarker.2. The method of claim 1 , wherein the method uses one or more selected from a white blood cell count claim 1 , a hemoglobin concentration claim 1 , a neutrophil count claim 1 , a lymphocyte count claim 1 , a monocyte count claim 1 , a procalcitonin concentration claim 1 , a C-reactive protein concentration claim 1 , an α1-acid glycoprotein concentration and an erythrocyte sedimentation rate of a specimen isolated from a human whole blood (blood) sample claim 1 , or a combination thereof as a biomarker.3. A method of simultaneously diagnosing active tuberculosis and latent tuberculosis infection (LTBI) claim 1 , comprising:providing a whole blood (blood) sample of a patient diagnosed as positive in a tuberculin skin test (TST) or an interferon-γ release assay (IGRA);obtaining one ...

Подробнее
11-01-2018 дата публикации

METHODS AND MATERIALS FOR ASSESSING AND TREATING ARTHRITIS

Номер: US20180010164A1
Автор: Taneja Veena

This document provides methods and materials involved in assessing mammals (e.g., humans) for arthritis. For example, methods and materials for assessing a mammal's gut microbial diversity to identify the mammal as having arthritis (e.g., rheumatoid arthritis) are provided. This document also provides methods and materials involved in treating arthritis. 1. A method for identifying a mammal as having arthritis , wherein said method comprises determining whether or not the gut of a mammal has an elevated level of gut microbial diversity of rarely represented genera , wherein the presence of said elevated level indicates that said mammal has arthritis , and wherein the absence of said elevated level indicates that said mammal does not have arthritis.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein said arthritis is rheumatoid arthritis.4Eggerthella, Collinsella, RikenellaPseudomonas.. The method of claim 1 , wherein said method comprises determining whether or not the gut of said mammal has an elevated level of gut microbial diversity of claim 1 , or5. The method of claim 1 , wherein said gut has an elevated level claim 1 , and said mammal is classified as having said arthritis.6. A method for treating arthritis claim 1 , wherein said method comprises:(a) identifying a mammal as having arthritis,(b) administering an antibiotic to said mammal to reduce the number of microbial organisms within the gut of said mammal, and{'i': Eggerthella, Collinsella', 'Pseudomonas, '(c) administering a formulation comprising live microbial organisms, wherein said formulation lacks species from the , and genera.'}7. The method of claim 6 , wherein said step (c) is performed between 2 days and 5 days after said step (b).8. A method for identifying a mammal as having arthritis claim 6 , wherein said method comprises determining whether or not a mammal has an elevated level of beta-alanine claim 6 , alpha-aminoadipic acid claim 6 , hydroxylysine. ...

Подробнее
14-01-2016 дата публикации

METHOD AND KIT FOR CYTOKINE ANALYSIS FROM A HUMAN WHOLE BLOOD SAMPLE

Номер: US20160011192A1
Автор: Wagner Ulf
Принадлежит: UNIVERSITY OF LEIPZIG

The invention relates to a method for prognostic evaluation of the disease progression of rheumatoid arthritis, in particular prognostic evaluation of the disease progression during treatment, and for the diagnosis and/or activity determination of rheumatoid arthritis by analysing cytokines from a human full blood sample. In the method according to the invention, a volume of a full blood sample of a human is transferred into at least one test tube containing a stimulating agent. As control samples, the same volume of a full blood sample of the human in each case is transferred into an empty test tube as a negative control and a test tube containing lipopolysaccharide as a positive control respectively. After incubation, the concentration of at least one proinflammatory cytokine is determined from the cell-free residue of each test tube. By way of an altered concentration of the at least one cytokine in the at least one test tube comprising the stimulating agent, the prognostic evaluation of the disease progression or the diagnosis is subsequently made. 1. Method for prognostic evaluation of the disease progression of rheumatoid arthritis by analysing cytokines from a human full blood sample , whereina volume of an isolated full blood sample of a human is transferred into at least one test tube containing a stimulating agent, and as control samples, the same volume of the full blood sample in each case is transferred into an empty test tube as a negative control and a test tube containing lipopolysaccharide as a positive control respectively,the respective test tubes along with the full blood samples contained therein are subsequently incubated at a temperature of 30-40° C.,the cell-free residue of each full blood sample is obtained from the test tubes and the concentration of at least one cytokine selected from TNF-α, IL-8, IFNγ, IL-10, IL-1β and IL-6 in the cell-free residue of each sample is detected,by way of an altered concentration of the at least one cytokine ...

Подробнее
14-01-2016 дата публикации

SALIVARY BIOASSAY FOR EARLY DETECTION OF BONE LOSS

Номер: US20160011206A1
Автор: FINE Daniel, Furgang David
Принадлежит:

The present invention is directed to methods to detect and diagnose osteoporosis and periodontal disease using salivary biomarkers. 1. A kit for detecting early-stage periodontal bone loss comprising a reagent that indicates the presence of a biomarker in a bodily fluid of a patient at a level that indicates early-stage periodontal bone loss and a device for contacting the bodily fluid with the biomarker.2. The kit of , further comprising instructions that explains that the presence of the biomarker at the level indicates early-stage periodontal bone loss. The kit of , wherein the bodily fluid is saliva.4. The kit of claim 1 , wherein the biomarker is selected from the group consisting of osteocalcin claim 1 , RANK L claim 1 , soluble RANKL claim 1 , osteoprotegrin claim 1 , alkaline phosphatase MIP 1α. 1 claim 1 ,25 dihyroxy Vitamin D claim 1 , 25-Hydroxy Vitamin D claim 1 , TRAP 5b claim 1 , TRACP 5b claim 1 , deoxypyridinoline claim 1 , FGF-23 claim 1 , PTH claim 1 , MMP 8 claim 1 , MMP 13 claim 1 , and alpha CTX-I.5. The kit if claim 1 , wherein the level is greater than about 200 pg/ml.6. The kit if claim 1 , wherein the level is greater than about 400 pg/ml.7. The kit if claim 1 , wherein the level is greater than about 600 pg/ml.8. The kit if claim 1 , wherein the reagent is a fluorophore.9. A kit for detecting osteoporosis comprising a reagent that indicates the presence of a biomarker in a bodily fluid of a patient at a level that indicates osteoporosis and a device for contacting the bodily fluid with the biomarker.10. The kit of claim 9 , further comprising instructions that explains that the presence of the biomarker at the level indicates osteoporosis11. The kit of claim 9 , wherein the bodily fluid is saliva.12. The kit of claim 9 , wherein the biomarker is selected from the group consisting of osteocalcin claim 9 , RANK L claim 9 , soluble RANKL claim 9 , osteoprotegrin claim 9 , alkaline phosphatase MIP 1α. 1 claim 9 ,25 dihyroxy Vitamin D claim 9 , ...

Подробнее
11-01-2018 дата публикации

METHODS FOR QUANTITATIVE ASSESSMENT OF MUSCLE FIBERS IN MUSCULAR DYSTROPHY

Номер: US20180011000A1
Принадлежит: Flagship Biosciences, Inc.

The disclosure concerns a method for assessing muscular dystrophy-linked protein expression in muscle fibers using digital image analysis of tissue. The method relates to assessing disease severity in individuals with muscular dystrophy. Muscle tissue samples are obtained from patients submitted for evaluation and processed to produce tissue sections mounted on glass slides which have been stained for a muscular dystrophy-linked protein. Digital images of the stained tissue sections are generated and analyzed by applying an algorithm process implemented by a computer to the images. The algorithm process extracts the morphometric and staining features of the muscular dystrophy-linked protein staining in the tissue, and parameters relating to these features are used to score the disease status for each patient submitted for evaluation. The score of disease status is ultimately used to infer disease severity, monitor the efficacy of a therapeutic approach, or select patients as candidates for a therapeutic approach. 1. A method comprising:capturing at least one digital image of at least one stained muscle tissue section;extracting at least one image analysis feature from each muscle fiber in the at least one digital image, wherein the at least one image analysis feature is selected from the group consisting of staining features and morphometric features;combining at least one staining and morphometric feature to derive a score of disease status; andinterpreting the score of disease status to draw inferences associated with the severity of disease.2. The method of claim 1 , wherein the at least one tissue section is stained for at least one muscular marker selected from the group consisting of a muscular dystrophy-linked protein and a muscle fiber membrane biomarker.3. The method of claim 2 , wherein the muscular dystrophy-linked protein is a protein product of a gene that when mutated claim 2 , or otherwise disrupted claim 2 , gives rise to at least one muscular ...

Подробнее
11-01-2018 дата публикации

Method of Diagnosing and Treating Asphyxia

Номер: US20180011111A1
Принадлежит: InfanDx AG

A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars. 1. Kit for carrying out a method for in vitro early diagnosing asphyxia , comprising:at least three compounds comprising enzymes, antibodies, or aptamers, wherein each of said compounds can bind to one of the asphyxia specific endogenous compounds as indicated in Tables 2 and 3,positive and/or negative controls, anda classification software for classification of the results achieved with the detection reagents.2. Kit according to claim 1 , wherein the kit comprises at least four compounds claim 1 , preferably at least five compounds claim 1 , comprising enzymes claim 1 , antibodies claim 1 , or aptamers claim 1 , wherein each of said compounds can bind to one of the asphyxia specific endogenous compounds as indicated in Tables 2 and 3.3. Method for in vitro monitoring of normoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy claim 1 , comprising:quantitatively detecting in at least one human blood sample at least three, preferably at least four, more preferably at least five asphyxia specific endogenous compounds from Tables 2 and 3; andcalibrating preprocessed detected values by means of training a linear discriminant analysis classifier with known stages of oxygenation and/or oxygen induced injuries of a human subject and applying the trained classifier to said preprocessed detected value data set ...

Подробнее
14-01-2021 дата публикации

Method for changing condition of eyelid of hairless animal

Номер: US20210011004A1
Автор: Hideki Miyake, Tomoko Oda
Принадлежит: Santen Pharmaceutical Co Ltd

A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.

Подробнее
10-01-2019 дата публикации

GDF15 IN GLAUCOMA AND METHODS OF USE THEREOF

Номер: US20190011458A1
Принадлежит:

The present disclosure provided methods for determining the severity of glaucoma using the expression levels of GDF15. Determining the severity of glaucoma aids in treatment decisions. 1. A method of determining glaucoma severity in a subject diagnosed with glaucoma , the method comprising:a) measuring the amount of gdf15 nucleic acid or GDF15 protein in a biological sample obtained from the subject;b) comparing the amount of gdf15 nucleic acid or GDF15 protein in the biological sample to a reference value; andc) determining the severity of glaucoma based on the amount of gdf15 nucleic acid or GDF15 protein relative to the reference value.2. The method of claim 1 , wherein the subject is diagnosed with mild to moderate glaucoma.3. The method of claim 1 , wherein the subject is not diagnosed with glaucoma but is at risk of having glaucoma.4. The method of claim 1 , wherein the subject is not diagnosed with glaucoma but is suspected of having glaucoma.5. The method of claim 1 , wherein the subject is determined to have Grade I claim 1 , Grade II or Grade III glaucoma based on the amount of gdf15 nucleic acid or GDF15 protein relative to the reference value.6. The method of claim 5 , wherein the subject is treated based on the grade of glaucoma.7. The method of claim 1 , wherein the biological sample is aqueous humor or retinal tissue.8. The method of claim 1 , wherein the biological sample is aqueous humor.9. The method of claim 8 , wherein the aqueous humor is collected at the beginning of surgery.10. The method of claim 1 , wherein GDF15 protein is detected.11. The method of claim 1 , wherein the amount of gdf15 nucleic acid or GDF15 protein above the reference value indicates Grade I claim 1 , Grade II or Grade III glaucoma.12. The method of claim 11 , wherein an amount of GDF15 protein of about 20 pg/ml to about 80 pg/ml indicates Grade I glaucoma; an amount of GDF15 protein of about 80 pg/ml to about 160 pg/ml indicates Grade II glaucoma; and an amount of GDF15 ...

Подробнее
10-01-2019 дата публикации

OSTEOMODULIN AND OSTEOMODULIN FRAGMENTS AS BIOMARKERS FOR OSTEOARTHRITIS AND USE THEREOF

Номер: US20190011459A1
Принадлежит: UNIVERSITE DE LIEGE

The present invention refers to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals. The present invention further refers to a method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the following steps: i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis. The present invention also provides an immunological binding partner specifically binding to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals and a kit comprising said immunological binding partner. 1. A method of detecting Osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein in mammals , preferably human individuals , comprising the step of measuring concentration of said osteomodulin protein or its fragment(s) in body fluids.2. The method according to claim 1 , wherein decreased expression or decreased concentration in body fluids of said osteomodulin protein or its fragment(s) compared to healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis.3. The method according to claim 2 , wherein said decreased expression or decreased concentration is measured in body fluids selected from the group consisting of urine claim 2 , secretions claim 2 , interstitial fluid claim 2 , blood claim 2 , synovial fluid claim 2 , serum claim 2 , spinal fluid lymph claim 2 , preferably ...

Подробнее
15-01-2015 дата публикации

DIAGNOSIS AND TREATMENT FOR RESPIRATORY TRACT DISEASES

Номер: US20150017099A1
Принадлежит:

The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. 1. A method for treating a respiratory infection in a subject , the method comprising:administering a composition to the respiratory tract of the subject, wherein the composition comprises an agent capable of activating a bitter taste signal pathway or inhibiting a sweet taste signal pathway in the subject, thereby treating the respiratory infection in the subject.2. The method of claim 1 , wherein the composition comprises at least one bitter taste receptor agonist.3. The method of claim 2 , wherein said at least one bitter taste receptor agonist is selected from the group consisting of denatonium benzoate and absinthin.4. The method of claim 1 , wherein said composition comprises at least one sweet taste receptor antagonist.5. The method of claim 4 , wherein said at least one sweet taste receptor antagonist is selected from the group consisting of lactisole claim 4 , a gymnemic acid claim 4 , ziziphin and hodulcine.6. The method of claim 1 , wherein said composition comprises a combination of at least ...

Подробнее
03-02-2022 дата публикации

Diagnosis of tuberculosis and other diseases using exhaled breath

Номер: US20220034854A1
Принадлежит: Zeteo Tech Inc

Disclosed are methods and devices for analyzing aerosol particles in exhaled breath using diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for capturing exhaled breath aerosols in a packed bed column and analyzing exhaled captured breath aerosols for tuberculosis diagnosis.

Подробнее
03-02-2022 дата публикации

COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS

Номер: US20220034885A1
Принадлежит:

The disclosure is directed to methods and kits for detecting neutralizing antibodies against a coronavirus (e.g., SARS-CoV-2) in a sample, such as a plasma sample or pooled plasma composition. The methods utilize a panel of SARS-CoV-2 neutralizing antibodies as a positive control. The kit may be a rapid detection kit that measures neutralizing antibodies using the provided methods. 1. A method of detecting coronavirus neutralizing antibodies in a sample , which method comprises:(a) contacting a sample with a solid support comprising a coronavirus cell receptor immobilized thereto to form a mixture;(b) contacting the mixture with a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein, whereby, if coronavirus neutralizing antibodies are present in the sample, the RBD binds to the coronavirus neutralizing antibodies and does not bind to the immobilized coronavirus cell receptor;(c) detecting and quantifying a signal from the reporter molecule, wherein the amount of detected signal is inversely proportional to the amount of coronavirus neutralizing antibodies present in the sample; and(d) performing steps (a)-(c) on a positive control comprising a panel of one or more coronavirus neutralizing monoclonal antibodies instead of the sample, and comparing the quantified signal of the positive control to the quantified signal of the sample to determine coronavirus neutralizing antibody capacity of the sample.2. A method of detecting coronavirus neutralizing antibodies in a sample , which method comprises:(a) contacting a sample with a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein to form a mixture, wherein the RBD binds to coronavirus neutralizing antibodies if present in the sample;(b) contacting the mixture with a solid support comprising a coronavirus cell receptor immobilized thereto, whereby, if ...

Подробнее
03-02-2022 дата публикации

Method of Determining Disease State Risk

Номер: US20220034895A1
Автор: Paul L. Wood
Принадлежит: Lincoln Memorial University

A method for determining colorectal cancer risk includes obtaining a blood sample of the subject, isolating serum or EDTA plasma from the blood sample, analyzing the serum or EDTA plasma to determine plasma levels of very long chain dicarboxylic acid (VLCDCA 28:4), comparing the determined plasmas level of VLCDCA 28:4 of the subject with a predetermined range of plasma levels of VLCDCA 28:4 of diagnosed subjects having colorectal cancer, and determining a colorectal cancer risk exists when the determined plasma level of VLCDCA 28:4 is within the predetermined range of plasma levels of VLCDCA.

Подробнее
03-02-2022 дата публикации

Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy

Номер: US20220034903A1

The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

Подробнее
21-01-2021 дата публикации

Method for Detecting and Monitoring Exhaled Breath

Номер: US20210015399A1
Автор: Gouma Pelagia I.
Принадлежит: Ohio State Innovation Foundation

A method for measuring levels of specific biomarkers in exhaled breath. Specific compounds such as nitric oxide and isoprene can be monitored from a subject's breath. The resultant measurements can provide indications of the subject's medical condition, or response to an applied stress. 1. A method for measuring levels of nitric oxide and isoprene in exhaled breath from a subject comprising:exhaling breath into a receiver;transferring the breath into a breath processing unit connected to the receiver and heated within a range of 25 to 400° C.;{'sub': 3', '3', '3', '3, 'contacting the exhaled breath with a surface of γ-WOinside the breath processing unit which responds to nitric oxide, and a surface of h-WOinside the breath processing unit which responds to isoprene to alter an electrical property of the γ-WOsurface and the h-WOsurface; and'}{'sub': 3', '3, 'correlating the electrical property of the γ-WOsurface with a concentration of nitric oxide in the exhaled breath, and the electrical property of the h-WOsurface with a concentration of isoprene in the exhaled breath.'}2. The method of wherein the receiver and the breath processing unit are integrated into a single combined unit.3. The method of wherein the surface of the γ-WOand the surface of h-WOare separately coupled to electrodes of platinum or gold.4. The method of wherein the electrodes are coupled to an alumina substrate.5. The method of wherein the breath processing unit is heated within a range of 150 to 400° C.6. The method of wherein the breath processing unit is heated within a range of 200 to 350° C.7. The method of wherein the breath processing unit is heated within a range of 250 to 350° C.8. The method of wherein the levels of nitric oxide and isoprene are monitored continuously.9. The method of wherein the subject is a fighter pilot operating an aircraft.10. The method of to evaluate for high altitude pulmonary edema.11. The method of to evaluate for asthma.12. The method of to evaluate for an ...

Подробнее
16-01-2020 дата публикации

METHODS AND SYSTEMS FOR PERIODONTAL DISEASE SCREENING

Номер: US20200015764A1
Принадлежит: NovoDynamics, Inc.

Teeth are screened for periodontal disease using digitized images manipulated and annotated on a processor. A digitized radiographic image of a tooth shows locations of a bone boundary and a cemento-enamel junction (CEJ) of the tooth. The digitized radiographic image is marked on the processor with a location on the bone boundary and with a pair of CEJ points at opposite ends of the CEJ visible in the radiograph. A ratio between (a) a distance between the bone boundary location and the adjacent CEJ point as numerator and (b) a distance between the CEJ points as denominator is calculated on the processor and compared with a threshold ratio-value for a corresponding tooth from a database accessible by the processor. A calculated ratio-value which is greater than the database threshold ratio-value is indicative of periodontal disease in the tooth. The probability of the correct diagnostic decision is determined by the relative magnitude of the calculated ratio-value and the threshold ratio-value. 1. A method performed on a processor for screening a tooth for periodontal disease , said method comprising:providing a digitized radiographic image of a tooth having a tooth number according to a tooth classification system, wherein the image shows a bone boundary and a cemento-enamel junction (CEJ) of the tooth;loading the digitized radiographic image on the processor,marking the digitized radiographic image on the processor with a location on the bone boundary and a pair of CEJ points at opposite ends of the CEJ;calculating on the processor a ratio between (a) a distance between the bone boundary location and the CEJ as numerator and (b) a distance between the CEJ points which represents a width of the tooth as denominator; andcomparing the ratio-value for the tooth calculated on the processor with a threshold ratio- value for a corresponding tooth from a database accessible by the processor, where a calculated ratio-value greater than the database threshold ratio-value is ...

Подробнее
15-01-2015 дата публикации

MEANS AND METHODS FOR ASSESSING BONE DISORDERS

Номер: US20150018237A1
Принадлежит: BASF SE

The present invention pertains to the field of diagnostics for bone disorders and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing a bone disorder. It also relates to a method for determining whether a compound is capable of inducing such a bone disorder in a subject and to a method of identifying a drug for treating a bone disorder. Furthermore, the present invention relates to a device and a kit for diagnosing a bone disorder. 1. A method for diagnosing bone disorder comprising:(a) determining the amount of at least one biomarker selected from any one of Tables 1a, 1b, 1c, 1d, 2a, 2b, 2c, or 2d in a test sample of a subject suspected to suffer from bone disorder, and(b) comparing the amounts determined in step (a) to a reference, whereby bone disorder is to be diagnosed.2. The method of claim 1 , wherein said subject has been brought into contact with a compound suspected to be capable of inducing bone disorder.3. A method of determining whether a compound is capable of inducing bone disorder in a subject comprising:(a) determining in a sample of a subject which has been brought into contact with a compound suspected to be capable of inducing bone disorder the amount of at least one biomarker selected from any one of Tables 1a, 1b, 1c, 1d, 2a, 2b, 2c, or 2d hematopoietic and(b) comparing the amounts determined in step (a) to a reference, whereby the capability of the compound to induce bone disorder is determined.4. The method of claim 2 , wherein said compound is at least one compound selected from the group consisting of: Sodium perchlorate claim 2 , Sodium fluoride claim 2 , Calcitonin (Salmon) and Calcium carbonate.5. The method of claim 1 , wherein said reference is derived from (i) a subject or group of subjects which suffers from bone disorder or (ii) a subject or group of subjects which has been brought into contact with at least one compound selected from the group consisting of: ...

Подробнее
18-01-2018 дата публикации

METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST

Номер: US20180016343A1
Принадлежит:

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. 1131-. (canceled)132. A method for reducing the incidence of one or more asthma exacerbations in a subject suffering from persistent asthma comprising administering to the subject a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R).133. The method of claim 132 , wherein the asthma exacerbation is selected from the group consisting of:(a) a 30% or greater reduction from baseline in morning peak expiratory flow (PEF) on two consecutive days;(b) six or more additional reliever puffs of albuterol or levalbuterol in a 24 hour period (compared to baseline) on two consecutive days; and (i) systemic (oral and/or parenteral) steroid treatment, or', '(ii) an increase in inhaled corticosteroids to at least 4 times the last dose received prior to discontinuation, or', '(iii) hospitalization., '(c) a deterioration of asthma requiring134. The method of claim 132 , wherein the pharmaceutical composition comprises 75 mg to 600 mg of the antibody or antigen-binding fragment thereof.135. The method of claim 132 , wherein the pharmaceutical composition is administered to the subject at a dosing frequency of once a week and/or the pharmaceutical composition administered to the subject systemically claim 132 , subcutaneously claim 132 , intravenously or intranasally.136. A method for improving one or more asthma-associated parameter(s) in a subject suffering from persistent asthma comprising administering to the subject a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) claim 132 , ...

Подробнее
18-01-2018 дата публикации

NOVEL METHODS FOR EARLY IDENTIFICATION OF BONE HEALING ABILITY IN INJURED PATIENTS

Номер: US20180016638A1
Принадлежит:

The present invention relates to the discovery that the expression levels of some RNA molecules, comprising messenger RNA (mRNA), non-coding RNA (ncRNA) and/or microRNA (miRNA), and protein can be used as a diagnostic signature to predict or monitor the bone healing ability in an acutely injured subject or in a chronic nonunion subject. In certain embodiments, the invention relates to methods and compositions useful for differentiating between a nonunion, slow healing, and/or normal healing of a fractured bone and treatment recommendations. The invention further includes a kit comprising biomarker probes for assessing the bone healing ability in an acutely injured subject or in a nonunion subject after receiving therapeutic treatment. 1. A method of identifying a subject with a fractured bone as a candidate for nonunion-mitigating intervention , or an additional intervention following a nonunion-mitigating intervention , the method comprising: "wherein a difference in level of the at least one RNA in the subject's sample as compared to the reference sample is indicative of a nonunion or slow healing of the fractured bone in the subject;", '(a) comparing the level of at least one RNA in a sample from the subject to a baseline level of the at least one RNA in a reference sample,'}or, "wherein a difference in the amount of change of the at least one RNA in the subject's samples as compared to the reference samples is indicative of a nonunion or slow healing of the fractured bone in the subject; and,", 'comparing the change of the level of at least one RNA between samples collected from the subject at two or more different times to a baseline change of the level of the at least one RNA in reference samples collected at different times,'}(b) recommending a nonunion-mitigating intervention for the subject.2. The method of claim 1 , further comprising determining the level of the at least one RNA molecule in a sample from the subject before performing step (a).3. A method ...

Подробнее
19-01-2017 дата публикации

Diagnosis of systemic lupus erythematosus using oligonucleotides antigens

Номер: US20170016895A1
Принадлежит: Yeda Research and Development Co Ltd

Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.

Подробнее
19-01-2017 дата публикации

BIOMARKERS AND METHODS FOR MEASURING AND MONITORING JUVENILE IDIOPATHIC ARTHRITIS ACTIVITY

Номер: US20170016896A1
Автор: Eastman Scott, Sasso Eric
Принадлежит:

Biomarkers useful for assessing inflammatory disease or flare activity, in particular in juvenile idiopathic arthritis, are provided, along with kits for measuring expression of the biomarkers. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. 1. A method for monitoring the presence or absence of juvenile idiopathic arthritis (JIA) disease activity in a subject , or for predicting flare activity in a subject having JIA , the method comprising:providing a test sample comprising a sample of bodily fluid taken from the mammal;determining sample concentrations for three or more biomarkers selected from the group consisting of alpha-2-macroglobulin (A2M); amyloid P component, serum (SAP); angiopoietin 1 (AGP1) antithrombin III (ATIII); ataxia telangiectasia mutated (ATM); B-cell activating factor (BAFF); chemokine (C-C motif) ligand 2 (CCL2); chemokine (C-C motif) ligand 3 (CCL3); chemokine (C-C motif) ligand 11 (CCL11); chemokine (C-C motif) ligand 22 (CCL22); chemokine (C-X-C motif) ligand 9 (CXCL9); chemokine (C-X-C motif) ligand 10 (CXCL10); CD40 ligand (CD40LG); C-reactive protein (CRP); complement C3; complement C4; complement factor H (CFH); epidermal growth factor (EGF); gelsolin (GSN); granzyme (GZM); haptoglobin (HP); heat shock protein 60 (HSP60); interleukin 6 (IL-6); leptin (LEP); MF; matrix metalloproteinase-1 (MMP1); matrix metalloproteinase-3 (MMP3); matrix metalloproteinase-9 (MMP9); resistin (RETN); serum amyloid (SAA); tumor necrosis factor receptor, type 1 (TNF-R1); vascular cell adhesion molecule-1 (VCAM1); vascular endothelial growth factor A (VEGF-A); Calprotectin; intercellular adhesion molecule 1 (ICAM-1); interleukin-1 beta (IL-1B); interleukin-6 receptor (IL-6R); interleukin-8 (IL-8); interleukin-8 (IL-10); interleukin-8 (IL-17); interleukin-8 (IL-18); interleukin-8 (IL-21); L-selectin; MDC; P-selectin; ...

Подробнее
19-01-2017 дата публикации

METHODS AND SYSTEM FOR DETERMINING THE DISEASE STATUS OF A SUBJECT

Номер: US20170016913A1
Принадлежит: OXFORD UNIVERSITY INNOVATION LIMITED

A method of determining the osteoarthritis, inflammatory arthritis or joint injury status in a subject, and a panel of test biomarkers for use in determining same is disclosed. In particular, the method comprise the steps of determining the expression levels of at least three test biomarkers in a sample of bodily fluid obtained from the subject; conducting a statistical analysis of the correlation and relative expression levels between the at least three biomarkers; calculating a statistical score based on the statistical analysis; and comparing the statistical score with reference statistical scores generated from at least three reference group expression profiles to predict, diagnose, monitor or determine one or more of osteoarthritis, inflammatory arthritis or joint injury. For both the method and panel the test biomarkers typically contains at least PIIANP. By analysis of the test biomarkers, the disease status of a subject may be determined. 1. A method of determining the osteoarthritis , inflammatory arthritis or joint injury status in a subject , the method comprising:determining the expression levels of at least three test biomarkers in a sample of bodily fluid obtained from the subject;conducting a statistical analysis of the correlation and relative expression levels between the at least three biomarkers;calculating a statistical score based on the statistical analysis; andcomparing the statistical score with reference statistical scores generated from at least three reference group expression profiles to predict, diagnose, monitor or determine one or more of osteoarthritis, inflammatory arthritis or joint injury, wherein the test biomarkers contains at least PIIANP.2. A panel of test biomarkers for use in determining the osteoarthritis status , inflammatory arthritis status or joint injury status of a subject or for predicting , diagnosing , monitoring , or determining osteoarthritis , inflammatory arthritis or joint injury in a subject , the panel ...

Подробнее
21-01-2016 дата публикации

Metabolic profiles

Номер: US20160018407A1
Принадлежит: Hpf Ip Holding Sa

The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. an autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders. Such disturbances can be normalised by treatment of the subject with specified compounds, particularly N-(2-chloro-3,4-dimethoxybenzylideneamino) guanidine or an aminoguanidine.

Подробнее
21-01-2016 дата публикации

USE OF SEPRASE FOR DIFFERENTIAL DIAGNOSIS OF ACUTE DYSPNEA

Номер: US20160018411A1
Принадлежит:

The present invention relates to a method for differentiating in a patient who suffers from acute shortness of breath (acute dyspnea) between pulmonary disease and cardiac disease. The method is based on measuring the levels of seprase and of a cardiac marker in a sample from said patient. Further envisaged are kits and devices adapted to carry out the method of the present invention.

Подробнее